<span style="font-family:&quot;font-size:medium;">沙库巴曲缬沙坦钠与培哚普利对老年HFrEF</span><span style="font-family:&quot;font-size:medium;">合并高血压患者疗效的研究</span>

李勇, 齐玉杰, 杨东伟

doi:10.2095-3593.2026.030008

中国药物评价 >

2026 , Vol. 43 >Issue 1: 62 - 62-67

DOI: https://doi.org/10.2095-3593.2026.030008

药品评价

沙库巴曲缬沙坦钠与培哚普利对老年HFrEF合并高血压患者疗效的研究

展开

郑州大学附属郑州中心医院，河南郑州 450000

李勇，男，主治医师，研究方向：冠状动脉粥样硬化性心脏病与心力衰竭的临床诊治

收稿日期: 2025-12-02

修回日期: 2025-12-24

录用日期: 2026-04-01

网络出版日期: 2026-04-01

收起

Comparative Efficacy of Sacubitril/Valsartan Sodium versus Perindopril in Elderly Patients with HFrEF and Hypertension

Expand

Zhengzhou Central Hospital Affiliated to Zhengzhou University， Henan Zhengzhou 450000， China

Received date: 2025-12-02

Revised date: 2025-12-24

Accepted date: 2026-04-01

Online published: 2026-04-01

Fold

摘要

目的：比较沙库巴曲缬沙坦钠与培哚普利治疗老年射血分数降低心力衰竭（HFrEF）合并高血压的疗效。方法：选择郑州大学附属郑州中心医院2024年1月至2025年6月收治的100例HFrEF伴高血压患者，采用随机数字表法和信封分配隐藏法分为口服培哚普利组（A组）和口服沙库巴曲缬沙坦钠组（B组），均50例。比较两组疗效、用药前后心功能、血压、血清因子、运动耐力、生活质量及预后情况。结果：A组患者治疗总有效率低于B组，不良反应总发生率及随访6个月后心力衰竭再入院比例高于B组（P＜0.05）。B组在心功能改善（LVEF 更高、LVEDD更低）、血压控制（收缩压与舒张压更低）、运动耐力（6MWD 更长）、炎症与纤维化生物标志物（NT-pro BNP、Gal-3、IL-6 水平更低）以及生活质量（MLHFQ评分更低）方面均优于A组（均P<0.05）。结论：在老年HFrEF合并高血压患者中，沙库巴曲缬沙坦钠在疗效、安全性及预后方面效果较好，可作为该类人群的治疗选择。

关键词： ; font-size:medium; ">心力衰竭；射血分数降低；高血压；沙库巴曲缬沙坦钠；培哚普利

本文引用格式

李勇, 齐玉杰, 杨东伟 . 沙库巴曲缬沙坦钠与培哚普利对老年HFrEF合并高血压患者疗效的研究[J]. 中国药物评价, 2026 , 43(1) : 62 -62-67 . DOI: 10.2095-3593.2026.030008

Abstract

Objective： To compare the efficacy of sacubitril/valsartan sodium versus perindopril in treating elderly patients with heart failure with reduced ejection fraction (HFrEF) and hypertension. Methods： A total of 100 patients with HFrEF and hypertension admitted to Zhengzhou Central Hospital Affiliated to Zhengzhou University between January 2024 and June 2025 were enrolled. Using the random number table and sealed-envelope allocation concealment method， they were divided into two groups： group A (oral perindopril， n=50) and group B (oral sacubitril/valsartan sodium， n=50). The therapeutic efficacy， cardiac function， blood pressure， serum biomarkers， exercise endurance， quality of life， and prognosis of the patients were compared between the two groups before and after treatment. Results： Compared with group B， group A had a lower total effective rate， and a higher total incidence of adverse reactions and proportion of heart failure readmission within 6 months， with statistically significant differences (P<0.05). Group B showed superior improvements in cardiac function (higher LVEF and lower LVEDD)， blood pressure control (lower systolic and diastolic blood pressure)， exercise endurance (longer 6MWD)， inflammatory and fibrotic biomarkers (lower levels of NT-pro BNP， Gal-3， and IL-6)， and quality of life (lower MLHFQ score) compared to group A (P<0.05). Conclusion： In elderly patients with HFrEF and hypertension， sacubitril/valsartan sodium demonstrates better efficacy， safety， and short-term prognosis， and may be considered as a preferable treatment option for this population.

Key words： ; font-size:medium; ">Heart failure； Reduced ejection fraction； Hypertension； Sacubitril/valsartan sodium； Perindopril

参考文献

[1] Mapelli M， Rubbo FM， Costantino S， et al. Pharmacological therapy of HFrEF in 2025： navigating new advances and old unmet needs in an eternal balance between progress and perplexities[J]. Card Fail Rev， 2025， 11(1)：e18-27.
     [2] Rashid AM， Khan MS， Fudim M， et al. Management of heart failure with reduced ejection fraction[J]. Curr Probl Cardiol， 2023， 48(5)：101596-101608.
     [3] Lang X， Peng C， Zhang Y， et al. Correlation between systolic blood pressure and mortality in heart failure patients with hypertension[J]. J Hypertens， 2024， 42(6)：1048-1056.
     [4] Kim Tran S， Truong AB， Nguyen PH， et al. Preliminary consequences of blood pressure management and blood homocysteine levels with perindopril in newly diagnosed hypertensive patients in the vietnamese population[J]. Int J Hypertens， 2023， 2023：1933783.
     [5] Bin Atan NMAS， Bin Hadi MF， Teoh VWY， et al. ARNI versus perindopril for remodeling in HFrEF： a cohort study[J]. J Cardiovasc Pharmacol Ther， 2023， 28：10742484231195019.
     [6] Yamamoto K， Yarimizu D， Shimanishi A， et al. Efficacy and safety of sacubitril/valsartan versus amlodipine in Japanese patients with essential hypertension： a randomized， multicenter， open-label， noninferiority study (PARASOL study)[J]. J Clin Hypertens (Greenwich)， 2025， 27(1)：e14938.
     [7] Shaddy R， Burch M， Kantor PF， et al. Sacubitril/valsartan in pediatric heart failure (PANORAMA-HF)： a randomized， multicenter， double-blind trial[J]. Circulation， 2024， 150(22)：1756-1766.
     [8] 中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会，中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018 [J]. 中华心血管病杂志， 2018， 46(10)：760-789.
     [9] Unger T， Borghi C， Charchar F， et al. 2020 International society of hypertension global hypertension practice guidelines[J]. Hypertension， 2020， 75(6)：1334-1357.
     [10] 中华医学会心血管病学分会，中国康复医学会心肺预防与康复专业委员会，中华心血管病杂志编辑委员会. 六分钟步行试验临床规范应用中国专家共识[J]. 中华心血管病杂志， 2020， 39(11)：1241-1250.
     [11] Catchpool M， Ramchand J， Hare DL， et al. Mapping the Minnesota living with heart failure questionnaire (MLHFQ) onto the assessment of quality of life 8D (AQoL-8D) utility scores[J]. Qual Life Res， 2020， 29(10)：2815-2822.
     [12] Du X， Wang X， Zhang R， et al. Standardized Rhodiola rosea injection for left ventricular remodeling and inflammation in patients with HFrEF： a systematic review and meta-analysis[J]. Front Pharmacol， 2025， 16：1536686.
     [13] Zhang G， Shi R， Li XM， et al. Impact of diabetes mellitus on right ventricular dysfunction and ventricular interdependence in hypertensive patients with heart failure with reduced ejection fraction assessed via 3.0 T cardiac MRI[J]. Cardiovasc Diabetol， 2024， 23(1)：375-385.
     [14] Zhang G， Li Y， Li XM， et al. Sex-related differences in left ventricular deformation in patients with hypertensive heart failure with reduced ejection fraction： assessment by cardiac magnetic resonance tissue tracking[J]. Curr Probl Cardiol， 2023， 48(5)：101601.
     [15] Connolly K， Batacan R JR， Jackson D， et al. Perindopril prevents development of obesity and hypertension in middle aged diet-induced obese rat models of metabolic syndrome[J]. Life Sci， 2023， 314：121291.
     [16] Zhang M， Zou Y， Li Y， et al. The history and mystery of sacubitril/valsartan： From clinical trial to the real world[J]. Front Cardiovasc Med， 2023， 10：1102521.
     [17] Lu H， Claggett BL， Packer M， et al. Effects of sacubitril/valsartan on all-cause hospitalizations in heart failure： post hoc analysis of the PARADIGM-HF and PARAGON-HF randomized clinical trials[J]. JAMA Cardiol， 2024， 9(11)：1047-1052.
     [18] Li Q， Fang Y， Peng DW， et al. Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats[J]. Eur J Pharmacol， 2023， 952：175754.
     [19] Shen M， Zheng C， Chen L， et al. LCZ696 (sacubitril/valsartan) inhibits pulmonary hypertension induced right ventricular remodeling by targeting pyruvate dehydrogenase kinase 4[J]. Biomed Pharmacother， 2023， 162：114569.
     [20] Lee V， Dalakoti M， Zheng Q， et al. Effects of sacubitril/valsartan on hypertensive heart disease： the REVERSE-LVH randomized phase 2 trial[J]. Nat Commun， 2025， 16(1)：6981-6990.
     [21] Liu X， Chen S， Pan H， et al. Predictive value of NT pro BNP for new-onset atrial fibrillation in heart failure and preserved ejection fraction[J]. ESC Heart Fail， 2024， 11(6)：4296-4307.
     [22] Xie B， Gao Q， Wang Y， et al. Effect of sacubitril-valsartan on left ventricular remodeling and NT-proBNP in patients with heart failure complicated with hypertension and reduced ejection fraction[J]. Am J Transl Res， 2024， 16(5)：1935-1944.
     [23] Luo Q， Zhang Q， Kong Y， et al. Heart failure， inflammation and exercise[J]. Int J Biol Sci， 2025， 21(8)：3324-3350.
     [24] Helleberg S， Engel A， Ahmed S， et al. Higher plasma IL-6 and PTX3 are associated with worse survival in left heart failure with pulmonary hypertension[J]. Am Heart J Plus， 2022， 20：100190.
     [25] Kurt B， Rex K， Reugels M， et al. Inflammatory biomarkers in heart failure： clinical perspectives on hsCRP， IL-6 and emerging candidates[J]. Curr Heart Fail Rep， 2025， 22(1)：35.
     [26] Liu C， Long Q， Yang H， et al. Sacubitril/Valsartan inhibits M1 type macrophages polarization in acute myocarditis by targeting C-type natriuretic peptide[J]. Biomed Pharmacother， 2024， 174：116535.
     [27] Zile MR， O′meara E， Claggett B， et al. Effects of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF[J]. J Am Coll Cardiol， 2019， 73(7)：795-806.

Options

文章导航

模态框（Modal）标题

摘要

本文引用格式

Abstract

参考文献